Last reviewed · How we verify
NCT05699226
Amplitude Titration to Improve ECT Clinical Outcomes
NA trial testing Soterix Medical Incorporated 4x1 adapter in Depression in 50 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | University of New Mexico |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 14 September 2023 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Soterix Medical Incorporated 4x1 adapter
- Traditional ECT device
Conditions studied
- Depression — all drugs for Depression →
- ECT — all drugs for ECT →
- Cognitive Change — all drugs for Cognitive Change →
Sponsor
University of New Mexico
Who can join
50 and older, any sex, with Depression or ECT. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05699226
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other University of New Mexico trials
Trials by the same sponsor.
- NCT07484906 — Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies · Phase 2 · withdrawn
- NCT07506395 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder · Phase 1 · not yet recruiting
- NCT07265973 — PREPARE: Perioperative REhabilitation Around Vaginal Prolapse RepAir Surgery for Recovery Enhancement · NA · recruiting
- NCT06982443 — Wellness, Alcohol, Vitals, and Emotions · NA · recruiting
- NCT06940609 — Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05699226 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of New Mexico
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05699226.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing